QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022

Author's Avatar
Jan 06, 2023

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023.